NCT03047473View on ClinicalTrials.gov

Avelumab in Patients With Newly Diagnosed Glioblastoma Multiforme

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

May 19, 2017

Primary Completion Date

August 9, 2021

Study Completion Date

August 9, 2021

Conditions
Glioblastoma Multiforme of Brain
Interventions
BIOLOGICAL

avelumab

add on of avelumab 10mg/kg IV to standard therapy

Trial Locations (1)

J8Y 1W2

Clinique Neuro-Outaouais, Gatineau

All Listed Sponsors
lead

Clinique Neuro-Outaouais

OTHER

NCT03047473 - Avelumab in Patients With Newly Diagnosed Glioblastoma Multiforme | Biotech Hunter | Biotech Hunter